Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 22 Feb 2019 Status changed from active, no longer recruiting to completed.
- 15 Nov 2018 Planned End Date changed from 31 Dec 2018 to 28 Jan 2019.
- 08 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018, according to ClinicalTrials.gov record.